Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 13/20 | 0.76 |
| ▸ | GRIA2 | P42262 | 7/20 | 0.76 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 6/20 | 0.43 |
| ▸ | FNTB | P49356 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138552 | 0.87 | GRIA4 (0.57) | GRIA4GRIA2PLA2G1BATG4BFNTA | |
| SCHEMBL5728529 | 0.78 | GRIA4 (0.73) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL3134036 | 0.77 | GRIA4 (1.00) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL13597802 | 0.77 | GRIA4 (0.54) | GRIA4GRIA2PLA2G1BATG4BFNTA | |
| SCHEMBL13597876 | 0.76 | PLA2G1B (0.56) | GRIA4GRIA2PLA2G1BATG4BFNTA | |
| SCHEMBL3137586 | 0.76 | GRIA4 (1.00) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL3125313 | 0.76 | GRIA4 (1.00) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL3128889 | 0.75 | GRIA4 (1.00) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL3126306 | 0.74 | GRIA4 (1.00) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL3138051 | 0.73 | GRIA4 (0.65) | GRIA4GRIA2FNTAFNTBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| WO-2005070916-A1 | THIOPHENE AND FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105852-A1 | Thiophene and furan compounds | PSEN2, PSEN1, TPMT | GRIA4 15/4885GRIA2 57/4885PLA2G1B 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.